| Year |
Citation |
Score |
| 2023 |
Shuman L, Pham J, Wildermuth T, Wu XR, Walter V, Warrick JI, DeGraff DJ. Urothelium-specific expression of mutationally activated Pik3ca initiates early lesions of non-invasive bladder cancer. The American Journal of Pathology. PMID 37544503 DOI: 10.1016/j.ajpath.2023.07.001 |
0.303 |
|
| 2022 |
Warrick JI, Hu W, Yamashita H, Walter V, Shuman L, Craig JM, Gellert LL, Castro MAA, Robertson AG, Kuo F, Ostrovnaya I, Sarungbam J, Chen YB, Gopalan A, Sirintrapun SJ, ... ... DeGraff DJ, et al. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nature Communications. 13: 6575. PMID 36323682 DOI: 10.1038/s41467-022-34251-3 |
0.328 |
|
| 2022 |
Walter V, DeGraff DJ, Yamashita H. Characterization of laminin-332 gene expression in molecular subtypes of human bladder cancer. American Journal of Clinical and Experimental Urology. 10: 311-319. PMID 36313206 |
0.337 |
|
| 2021 |
Torab P, Yan Y, Ahmed M, Yamashita H, Warrick JI, Raman JD, DeGraff DJ, Wong PK. Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation. Cells. 10. PMID 34831307 DOI: 10.3390/cells10113084 |
0.35 |
|
| 2021 |
Iyyanki T, Zhang B, Wang Q, Hou Y, Jin Q, Xu J, Yang H, Liu T, Wang X, Song F, Luan Y, Yamashita H, Chien R, Lyu H, Zhang L, ... ... DeGraff DJ, et al. Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. Genome Biology. 22: 105. PMID 33858483 DOI: 10.1186/s13059-021-02325-y |
0.386 |
|
| 2020 |
Connelly ZM, Jin R, Zhang J, Yang S, Cheng S, Shi M, Cates JM, Shi R, DeGraff DJ, Nelson PS, Liu Y, Morrissey C, Corey E, Yu X. FOXA2 promotes prostate cancer growth in the bone. American Journal of Translational Research. 12: 5619-5629. PMID 33042443 |
0.323 |
|
| 2020 |
Torab P, Yan Y, Yamashita H, Warrick JI, Raman JD, DeGraff DJ, Wong PK. Three-Dimensional Microtumors for Probing Heterogeneity of Invasive Bladder Cancer. Analytical Chemistry. PMID 32579350 DOI: 10.1021/Acs.Analchem.0C00057 |
0.491 |
|
| 2020 |
Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews. Urology. PMID 32235944 DOI: 10.1038/S41585-020-0304-1 |
0.39 |
|
| 2020 |
Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, Phaeton R, Hossler C, Rosenberg J, DeGraff D, Shuman L, Broach JR, Warrick JI. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. PMID 32187665 DOI: 10.1002/Cncr.32822 |
0.395 |
|
| 2020 |
Li H, Zhang Q, Shuman L, Kaag M, Raman JD, Merrill S, DeGraff DJ, Warrick JI, Chen G. Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Scientific Reports. 10: 1439. PMID 31996725 DOI: 10.1038/S41598-020-58351-6 |
0.306 |
|
| 2020 |
Shuman* L, Buckwalter J, Wildermuth T, Kaestner K, Mendelsohn C, DeGraff D. MP28-17 FOXA1 EXPRESSION IS REQUIRED FOR MAINTENANCE OF SUPERFICIAL UMBRELLA CELLS IN THE UROTHELIUM The Journal of Urology. 203: e426. DOI: 10.1097/Ju.0000000000000867.017 |
0.357 |
|
| 2020 |
Buckwalter* J, Groeneveld C, Tang P, Yamashita H, Robertson AG, Castro M, DeGraff D. MP17-12 IDENTIFICATION OF FOXA1 AS A MASTER REGULATOR OF PPAR[Latin Small Letter Gamma] ACTION IN BLADDER CANCER The Journal of Urology. 203: e230-e231. DOI: 10.1097/Ju.0000000000000842.012 |
0.428 |
|
| 2019 |
Yamashita H, Kawasawa YI, Shuman L, Zheng Z, Tran T, Walter V, Warrick JI, Chen G, Al-Ahmadie H, Kaag M, Wong PK, Raman JD, DeGraff DJ. Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis. 8: 69. PMID 31772149 DOI: 10.1038/s41389-019-0178-3 |
0.382 |
|
| 2019 |
Osei-Amponsa V, Buckwalter JM, Shuman L, Zheng Z, Yamashita H, Walter V, Wildermuth T, Ellis-Mohl J, Liu C, Warrick JI, Shantz LM, Feehan RP, Al-Ahmadie H, Mendelsohn C, Raman JD, ... ... DeGraff DJ, et al. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. Oncogene. PMID 31636388 DOI: 10.1038/S41388-019-1063-4 |
0.5 |
|
| 2019 |
Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, ... ... DeGraff DJ, et al. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports. 28: 1971-1980.e8. PMID 31433975 DOI: 10.1016/J.Celrep.2019.07.084 |
0.34 |
|
| 2019 |
Buckwalter JM, Chan W, Shuman L, Wildermuth T, Ellis-Mohl J, Walter V, Warrick JI, Wu XR, Kaag M, Raman JD, DeGraff DJ. Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems. International Journal of Molecular Sciences. 20. PMID 31137849 DOI: 10.3390/Ijms20102599 |
0.457 |
|
| 2019 |
Yee CH, Zheng Z, Shuman L, Yamashita H, Warrick JI, Wu XR, Raman JD, DeGraff DJ. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS. Scientific Reports. 9: 270. PMID 30670749 DOI: 10.1038/S41598-018-36720-6 |
0.476 |
|
| 2019 |
Connelly ZM, Yang S, Khater N, Orr AW, Jin R, Degraff D, Morrissey C, Corey E, Matusik R, Yu X. Abstract 59: The pioneer transcription factor FOXA2 regulates integrin alpha 1 expression controlling prostate cancer bone colonization Cancer Research. 79: 59-59. DOI: 10.1158/1538-7445.Sabcs18-59 |
0.502 |
|
| 2019 |
Buckwalter* J, Amponsa VO, Shuman L, Walter V, Warrick J, Wu X, Raman J, DeGraff D. MP51-11 EPIGENETIC REGULATION OF
FORKHEAD BOX A1
IN ADVANCED BLADDER CANCER Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556477.92376.Ee |
0.385 |
|
| 2019 |
Shuman* L, Osei-Amponsa V, Buckwalter J, Zheng Z, Yamashita H, Walter V, Ellis J, Lu C, Warrick J, Shantz L, Feehan R, Al-Ahmadie H, Mendelsohn C, Kaestner K, Wu X, ... DeGraff D, et al. MP51-12 INACTIVATION OF FOXA1 COOPERATES WITH PTEN COPY NUMBER LOSS IN BLADDER CANCER TO PROMOTE TUMOR HETEROGENEITY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556472.61882.0A |
0.442 |
|
| 2018 |
Warrick JI, Sjödahl G, Kaag M, Raman JD, Merrill S, Shuman L, Chen G, Walter V, DeGraff DJ. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. European Urology. PMID 30266310 DOI: 10.1016/J.Eururo.2018.09.003 |
0.417 |
|
| 2018 |
Yamashita H, Shuman L, Warrick JI, Raman JD, Degraff DJ. Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. American Journal of Clinical and Experimental Urology. 6: 164-171. PMID 30246052 |
0.446 |
|
| 2018 |
Osei Amponsa V, Zheng Z, Walter V, Warrick J, Mendelsohn C, Kaestner K, Wu X, Raman J, DeGraff D. Novel transgenic knockout model of basal-squamous bladder cancer. Journal of Clinical Oncology. 36: 459-459. DOI: 10.1200/Jco.2018.36.6_Suppl.459 |
0.414 |
|
| 2018 |
Shuman L, Yamashita H, Zheng Z, Tran T, Osei-Amponsa V, Warrick J, Kaag M, Raman J, Williams T, DeGraff D. MP54-01 TRANSCRIPTION FACTOR ACTIVATOR PROTEIN 2 FAMILY MEMBERS ARE MARKERS OF THE BASAL MOLECULAR SUBTYPE OF HUMAN BLADDER CANCER AND REPRESSED BY LUMINAL TRANSCRIPTIONAL MASTER REGULATORS Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1692 |
0.391 |
|
| 2017 |
Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA. Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer (Amsterdam, Netherlands). 3: 211-223. PMID 28824949 DOI: 10.3233/BLC-170111 |
0.353 |
|
| 2017 |
Warrick JI, Kaag M, Raman JD, Chan W, Tran T, Kunchala S, Shuman L, DeGraff D, Chen G. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. Virchows Archiv : An International Journal of Pathology. PMID 28721490 DOI: 10.1007/S00428-017-2190-3 |
0.358 |
|
| 2017 |
Shuman L, Zheng Z, Yamashita H, Warrick J, Kaestner K, DeGraff D. MP98-12 FOXA1 KNOCKOUT IS ASSOCIATED WITH INCREASED CARCINOGENIC SUSCEPTIBILITY AND ANDROGEN RECEPTOR EXPRESSION IN MURINE BLADDER CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3077 |
0.506 |
|
| 2017 |
Osei-Amponsa V, Zheng Z, Bouza S, Warrick J, Mendelsohn C, Kaestner K, Wu X, DeGraff D. MP65-16 INACTIVATION OF FOXA1 AND PTEN RESULTS IN DEVELOPMENT OF CARCINOMA IN SITU AND THE BASAL SUBTYPE OF MUSCLE INVASIVE BLADDER CANCER FOLLOWING CARCINOGEN EXPOSURE Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2010 |
0.383 |
|
| 2016 |
Warrick JI, Walter V, Yamashita H, Chung E, Shuman L, Amponsa VO, Zheng Z, Chan W, Whitcomb TL, Yue F, Iyyanki T, Kawasawa YI, Kaag M, Guo W, Raman JD, ... ... DeGraff DJ, et al. FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports. 6: 38531. PMID 27924948 DOI: 10.1038/Srep38531 |
0.493 |
|
| 2016 |
Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, DeGraff DJ. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nature Reviews. Urology. PMID 27898096 DOI: 10.1038/Nrurol.2016.239 |
0.516 |
|
| 2016 |
Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, ... ... DeGraff DJ, et al. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) is Associated with Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. PMID 27215483 DOI: 10.1016/J.Urology.2016.05.030 |
0.32 |
|
| 2016 |
Warrick JI, Raman JD, Kaag M, Bruggeman T, Cates J, Clark P, DeGraff DJ. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. Urologic Oncology. 34: 258.e1-6. PMID 26976725 DOI: 10.1016/J.Urolonc.2016.02.011 |
0.479 |
|
| 2016 |
Chan W, Tran T, Yamashita H, Zheng Z, Osei Amponsa V, Imamura Y, Warrick J, Raman J, DeGraff D. MP83-03 EXPRESSION OF TRANSCRIPTION FACTOR AP2 (TFAP2) FAMILY MEMBERS ARE ASSOCIATED WITH THE BASAL MOLECULAR SUBTYPE OF HUMAN BLADDER CANCER AND ALTERED NOTCH PATHWAY ACTIVITY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2185 |
0.426 |
|
| 2016 |
Chan W, Warrick J, Shuman L, Zheng Z, Yamashita H, Osei Amponsa V, Raman J, DeGraff D. PD38-03 CHARACTERIZATION OF CELL BASED MODELS FOR THE IN VITRO AND IN VIVO STUDY OF DISCRETE MOLECULAR SUBTYPES IN BLADDER CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1483 |
0.365 |
|
| 2015 |
Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ. Nfib regulates transcriptional networks that control the development of prostatic hyperplasia. Endocrinology. en20151312. PMID 26677878 DOI: 10.1210/En.2015-1312 |
0.535 |
|
| 2015 |
Adam RM, DeGraff DJ. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder. Urologic Oncology. 33: 444-50. PMID 26254697 DOI: 10.1016/J.Urolonc.2015.06.006 |
0.409 |
|
| 2015 |
Vasekar M, Degraff D, Joshi M. Immunotherapy in Bladder Cancer. Current Molecular Pharmacology. PMID 26177642 DOI: 10.2174/1874467208666150716120945 |
0.452 |
|
| 2015 |
Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, ... ... DeGraff DJ, et al. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. The American Journal of Pathology. 185: 1385-95. PMID 25907831 DOI: 10.1016/J.Ajpath.2015.01.014 |
0.445 |
|
| 2015 |
Yamashita H, Zheng Z, Osei Amponsa V, Raman J, DeGraff D. MP68-10 EXPRESSION OF TFAP2C IS ASSOCIATED WITH THE BASAL MOLECULAR SUBTYPE OF BLADDER CANCER AND INCREASED TUMOR AGGRESSIVENESS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2472 |
0.462 |
|
| 2014 |
Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ. SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer and Prostatic Diseases. 17: 301-9. PMID 25091041 DOI: 10.1038/Pcan.2014.29 |
0.528 |
|
| 2014 |
Lin-Tsai O, Taylor JA, Clark PE, Adam RM, Wu XR, DeGraff DJ. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Current Opinion in Urology. 24: 512-6. PMID 24921908 DOI: 10.1097/Mou.0000000000000087 |
0.453 |
|
| 2014 |
DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. Laboratory Investigation; a Journal of Technical Methods and Pathology. 94: 726-39. PMID 24840332 DOI: 10.1038/Labinvest.2014.64 |
0.519 |
|
| 2014 |
Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, et al. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Molecular Endocrinology (Baltimore, Md.). 28: 949-64. PMID 24801505 DOI: 10.1210/Me.2013-1213 |
0.442 |
|
| 2014 |
Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Reviews. 33: 377-97. PMID 24452759 DOI: 10.1007/S10555-013-9487-8 |
0.496 |
|
| 2013 |
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, et al. SPARCL1 suppresses metastasis in prostate cancer. Molecular Oncology. 7: 1019-30. PMID 23916135 DOI: 10.1016/J.Molonc.2013.07.008 |
0.535 |
|
| 2013 |
Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K, Degraff DJ, Pilbeam CC, Taylor JA. Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis. 34: 2891-9. PMID 23825153 DOI: 10.1093/Carcin/Bgt239 |
0.462 |
|
| 2013 |
Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia (New York, N.Y.). 15: 749-60. PMID 23814487 DOI: 10.1593/Neo.121956 |
0.46 |
|
| 2013 |
Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. Plos One. 8: e60983. PMID 23577181 DOI: 10.1371/Journal.Pone.0060983 |
0.512 |
|
| 2013 |
DeGraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, Liebert M, Wu XR, Taylor JA. Current preclinical models for the advancement of translational bladder cancer research. Molecular Cancer Therapeutics. 12: 121-30. PMID 23269072 DOI: 10.1158/1535-7163.Mct-12-0508 |
0.473 |
|
| 2013 |
Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW. Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. The American Journal of Pathology. 182: 449-59. PMID 23219716 DOI: 10.1016/J.Ajpath.2012.10.007 |
0.499 |
|
| 2013 |
DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urologic Oncology. 31: 802-11. PMID 21924649 DOI: 10.1016/J.Urolonc.2011.07.017 |
0.436 |
|
| 2013 |
Majumdar S, Gong E, Vizio DD, Dreyfuss J, DeGraff D, Hager M, Park P, Bellmunt J, Matusik R, Rosenberg J, Adam R. Abstract 4066: Loss of Sh3gl2/endophilin A1 is an early event in urothelial carcinoma that regulates malignant behavior. Cancer Research. 73: 4066-4066. DOI: 10.1158/1538-7445.Am2013-4066 |
0.485 |
|
| 2012 |
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. Plos One. 7: e36669. PMID 22590586 DOI: 10.1371/Journal.Pone.0036669 |
0.537 |
|
| 2012 |
DeGraff DJ, Matusik RJ. Gender specific differences in bladder cancer. The Journal of Urology. 188: 10-1. PMID 22583637 DOI: 10.1016/J.Juro.2012.04.037 |
0.423 |
|
| 2011 |
DeGraff DJ, Clark PE. Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspective. European Urology. 60: 239-40. PMID 21195537 DOI: 10.1016/J.Eururo.2010.12.023 |
0.489 |
|
| 2010 |
Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 30: 1868-79. PMID 21151173 DOI: 10.1038/Onc.2010.560 |
0.433 |
|
| 2010 |
Degraff DJ, Aguiar AA, Chen Q, Adams LK, Williams BJ, Sikes RA. Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells. American Journal of Translational Research. 2: 200-8. PMID 20407609 |
0.734 |
|
| 2010 |
Zhang J, Gao N, DeGraff DJ, Yu X, Sun Q, Case TC, Kasper S, Matusik RJ. Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression. The Prostate. 70: 934-51. PMID 20209642 DOI: 10.1002/Pros.21128 |
0.461 |
|
| 2010 |
Chen Q, DeGraff DJ, Sikes RA. The developmental expression profile of PAX2 in the murine prostate. The Prostate. 70: 654-65. PMID 20017165 DOI: 10.1002/Pros.21099 |
0.719 |
|
| 2010 |
DeGraff DJ. Novel use of a combined artificial intelligence approach to identify patients with noninvasive urothelial cell carcinoma of the urinary bladder who are at greatest risk for progression to muscle-invasive disease: a step forward. European Urology. 57: 407-8; discussion 40. PMID 19945780 DOI: 10.1016/J.Eururo.2009.11.036 |
0.365 |
|
| 2010 |
Boachie AM, Degraff D, Yu X, Sun Q, Friedman D, Gronostajski R, Matusik R. Abstract 1231: Nuclear Factor I family members interact with FoxA1 to regulate androgen responsive promoters Cancer Research. 70: 1231-1231. DOI: 10.1158/1538-7445.Am10-1231 |
0.482 |
|
| 2009 |
Degraff DJ, Aguiar AA, Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. American Journal of Translational Research. 1: 115-30. PMID 19956425 |
0.731 |
|
| 2009 |
Sun Q, Yu X, Degraff DJ, Matusik RJ. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Molecular Endocrinology (Baltimore, Md.). 23: 2038-47. PMID 19846536 DOI: 10.1210/Me.2009-0092 |
0.477 |
|
| 2007 |
Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. Journal of Cellular Physiology. 213: 261-8. PMID 17492783 DOI: 10.1002/Jcp.21123 |
0.736 |
|
| Show low-probability matches. |